Novartis AG/€NOVN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Novartis AG
Novartis AG is a global healthcare company based in Switzerland, specializing in the research, development, manufacturing, and marketing of a broad range of pharmaceutical products. The company's core business is centered around patented prescription medicines in areas such as oncology, cardiovascular, immunology, neuroscience, and ophthalmology. Formed in 1996 from the merger of Ciba-Geigy and Sandoz, Novartis operates in over 150 countries worldwide. Its strategic positioning is reinforced by significant investments in research and development, supporting a robust pipeline of innovative therapies. The company is headquartered in Basel, Switzerland, and emphasizes its competitive strength through advanced research capabilities and a diverse product portfolio.
- Ticker
- €NOVN
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 75,267
- Headquarters
- Basel, Switzerland
- Website
- www.novartis.com
Novartis AG Metrics
BasicAdvanced
€262B
23.10
€5.92
0.49
€4.09
2.99%
Price and volume
Market cap
€262B
Beta
0.49
52-week high
€144.30
52-week low
€104.56
Average daily volume
3.3M
Dividend rate
€4.09
Financial strength
Current ratio
0.862
Quick ratio
0.55
Long term debt to equity
0.933
Total debt to equity
1.169
Dividend payout ratio (TTM)
71.08%
Interest coverage (TTM)
13.36%
Profitability
EBITDA (TTM)
20,680.101
Gross margin (TTM)
74.98%
Net profit margin (TTM)
22.50%
Operating margin (TTM)
32.75%
Effective tax rate (TTM)
17.88%
Revenue per employee (TTM)
€671,490
Management effectiveness
Return on assets (TTM)
10.25%
Return on equity (TTM)
30.35%
Valuation
Price to earnings (TTM)
23.101
Price to revenue (TTM)
5.156
Price to book
5.83
Price to tangible book (TTM)
-8.88
Price to free cash flow (TTM)
19.302
Free cash flow yield (TTM)
5.18%
Free cash flow per share (TTM)
7.088
Dividend yield (TTM)
2.99%
Forward dividend yield
2.99%
Growth
Revenue change (TTM)
2.73%
Earnings per share change (TTM)
-3.43%
3-year revenue growth (CAGR)
8.37%
10-year revenue growth (CAGR)
1.32%
3-year earnings per share growth (CAGR)
22.59%
10-year earnings per share growth (CAGR)
8.97%
3-year dividend per share growth (CAGR)
10.48%
10-year dividend per share growth (CAGR)
5.64%
What the Analysts think about Novartis AG
Analyst ratings (Buy, Hold, Sell) for Novartis AG stock.
Analyst projections of the future price of Novartis AG stock.
Bulls say / Bears say
Novartis returned to sales growth in Q2, with Kisqali, Kesimpta, Scemblix and Pluvicto growing strongly. These newer brands give it a growing base to offset declines in older medicines. (GlobeNewswire)
Remibrutinib beat teriflunomide in two Phase III trials for relapsing multiple sclerosis and also showed benefits on key secondary measures. Success in this additional indication could expand the drug’s commercial potential. (Reuters)
A UK court rejected a challenge to an Entresto patent, a boost to Novartis as it faces wider patent expiries. The ruling blocks a planned UK generic launch while supplementary protection remains in place until 2028. (Reuters)
Generic competition is sharply eroding Entresto sales, and the pressure is not limited to that drug. Novartis still expects low-single-digit sales growth but a low-single-digit decline in core operating income for 2026. (Reuters)
Recent clinical setbacks weaken the pipeline’s ability to replace medicines losing exclusivity: del-desiran missed its late-stage trial goal, Novartis halted an ALS programme after a mid-stage failure, and it paused rap-cel studies after three deaths. Together, these events raise the risk that future products will not arrive as hoped. (Reuters, Reuters)
Novartis’s chief executive warned that US most-favoured-nation drug pricing could create a very difficult situation and force hard trade-offs. If overseas governments do not change how they reward new medicines, launches and access could be affected. (CNBC)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
Novartis AG Financial Performance
Revenues and expenses
Novartis AG Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Novartis AG
AllUSDEURGBP
Fund name | Fund size | €NOVN weighting |
|---|---|---|
SPDR MSCI World Health Care$WHEA | $708M | 3.21% |
SPDR MSCI World Health Care£HEAW | $708M | 3.21% |
Xtrackers MSCI World Health Care$XDWH | $4.1B | 3.21% |
Xtrackers MSCI World Health Care£XWHS | $4.1B | 3.21% |
Vanguard ESG Developed Europe All Cap£V3EL | €35M | 2.51% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.